These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 35593483)

  • 1. Comprehensive genomic profiling in advanced/metastatic colorectal cancer: number needed to test and budget impact of expanded first line use.
    Proudman D; DeVito NC; Belinson S; Allo MA; Morris ED; Signorovitch J; Patel AK
    J Med Econ; 2022; 25(1):817-825. PubMed ID: 35593483
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Budget impact analysis of comprehensive genomic profiling in patients with advanced non-small cell lung cancer.
    Signorovitch J; Zhou Z; Ryan J; Anhorn R; Chawla A
    J Med Econ; 2019 Feb; 22(2):140-150. PubMed ID: 30430885
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Budget impact analysis of comprehensive genomic profiling for untreated advanced or recurrent solid cancers in Japan.
    Tang W; Hanada K; Motoo Y; Sakamaki H; Oda T; Furuta K; Abutani H; Ito S; Tsutani K
    J Med Econ; 2023; 26(1):614-626. PubMed ID: 37073487
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Budget Impact Analysis of Comprehensive Genomic Profiling in Patients With Advanced Non-Small-Cell Lung Cancer.
    Harvey MJ; Cunningham R; Sawchyn B; Montesion M; Reddy P; McBride A; Chawla AJ
    JCO Precis Oncol; 2021 Nov; 5():1611-1624. PubMed ID: 34994647
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-Effectiveness of Tumor Genomic Profiling to Guide First-Line Targeted Therapy Selection in Patients With Metastatic Lung Adenocarcinoma.
    Dong OM; Poonnen PJ; Winski D; Reed SD; Vashistha V; Bates J; Kelley MJ; Voora D
    Value Health; 2022 Apr; 25(4):582-594. PubMed ID: 35365302
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumour mutational burden, microsatellite instability, and actionable alterations in metastatic colorectal cancer: Next-generation sequencing results of TRIBE2 study.
    Antoniotti C; Korn WM; Marmorino F; Rossini D; Lonardi S; Masi G; Randon G; Conca V; Boccaccino A; Tomasello G; Passardi A; Swensen J; Ugolini C; Oberley M; Tamburini E; Casagrande M; Domenyuk V; Fontanini G; Giordano M; Abraham J; Spetzler D; Falcone A; Lenz HJ; Cremolini C
    Eur J Cancer; 2021 Sep; 155():73-84. PubMed ID: 34365081
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of a Collaboration Between a Health Plan, Oncology Practice, and Comprehensive Genomic Profiling Company from the Payer Perspective.
    Reitsma M; Fox J; Borre PV; Cavanaugh M; Chudnovsky Y; Erlich RL; Gribbin TE; Anhorn R
    J Manag Care Spec Pharm; 2019 May; 25(5):601-611. PubMed ID: 30632889
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost of genetic testing, delayed care, and suboptimal treatment associated with polymerase chain reaction versus next-generation sequencing biomarker testing for genomic alterations in metastatic non-small cell lung cancer.
    Bestvina CM; Waters D; Morrison L; Emond B; Lafeuille MH; Hilts A; Lefebvre P; He A; Vanderpoel J
    J Med Econ; 2024; 27(1):292-303. PubMed ID: 38391239
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Total cost of testing for genomic alterations associated with next-generation sequencing versus polymerase chain reaction testing strategies among patients with metastatic non-small cell lung cancer.
    Vanderpoel J; Stevens AL; Emond B; Lafeuille MH; Hilts A; Lefebvre P; Morrison L
    J Med Econ; 2022; 25(1):457-468. PubMed ID: 35289703
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comprehensive Genomic Profiling (CGP)-Informed Personalized Molecular Residual Disease (MRD) Detection: An Exploratory Analysis from the PREDATOR Study of Metastatic Colorectal Cancer (mCRC) Patients Undergoing Surgical Resection.
    Lonardi S; Nimeiri H; Xu C; Zollinger DR; Madison RW; Fine AD; Gjoerup O; Rasola C; Angerilli V; Sharma S; Wu HT; Palsuledesai CC; Malhotra M; Aleshin A; Loupakis F; Renkonen E; Hegde P; Fassan M
    Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232827
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Budget impact of capmatinib for adults with metastatic non-small cell lung cancer harboring a
    Cai B; Zhou ZY; Xue W; Hazra NC; Singh M; Mishra D; Brixner D; Oderda G; Biskupiak J
    J Med Econ; 2021; 24(1):131-139. PubMed ID: 33397178
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Broad Detection of Alterations Predicted to Confer Lack of Benefit From EGFR Antibodies or Sensitivity to Targeted Therapy in Advanced Colorectal Cancer.
    Rankin A; Klempner SJ; Erlich R; Sun JX; Grothey A; Fakih M; George TJ; Lee J; Ross JS; Stephens PJ; Miller VA; Ali SM; Schrock AB
    Oncologist; 2016 Nov; 21(11):1306-1314. PubMed ID: 27682134
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Questionnaire Survey on the Timing of Comprehensive Genomic Profiling for Advanced Recurrent Colorectal Cancer and Its Impact on Patients].
    Yarimizu A; Kuribayashi M; Nomura K; Kimura K; Takenaka Y; Song J; Ohashi E; Nishimura Y; Demachi T; Hirata M; Beppu N; Uchino M; Ikeuchi H; Ikeda M; Kataoka K
    Gan To Kagaku Ryoho; 2023 Aug; 50(8):891-893. PubMed ID: 37608415
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Integrated budget impact model to estimate the impact of introducing selpercatinib as a tumor-agnostic treatment option for patients with
    Bhandari NR; Gilligan AM; Myers J; Ale-Ali A; Smolen L
    J Med Econ; 2024; 27(1):348-358. PubMed ID: 38334069
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Budget Impact of Next-Generation Sequencing for Molecular Assessment of Advanced Non-Small Cell Lung Cancer.
    Yu TM; Morrison C; Gold EJ; Tradonsky A; Arnold RJG
    Value Health; 2018 Nov; 21(11):1278-1285. PubMed ID: 30442274
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comprehensive Genomic Profiling of Carcinoma of Unknown Primary Origin: Retrospective Molecular Classification Considering the CUPISCO Study Design.
    Ross JS; Sokol ES; Moch H; Mileshkin L; Baciarello G; Losa F; Beringer A; Thomas M; Elvin JA; Ngo N; Jin DX; Krämer A
    Oncologist; 2021 Mar; 26(3):e394-e402. PubMed ID: 33219618
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The budget impact of adding pralsetinib to a US health plan formulary for treatment of non-small cell lung cancer and thyroid cancer with
    Duff S; Bargiacchi F; Norregaard C; Brener M; Sullivan E
    J Manag Care Spec Pharm; 2022 Feb; 28(2):218-231. PubMed ID: 34726500
    [No Abstract]   [Full Text] [Related]  

  • 18. Cost-effectiveness of pembrolizumab for the first-line treatment of patients with unresectable or metastatic MSI-H/dMMR colorectal cancer in the United States.
    Aguiar-Ibáñez R; Hardern C; van Hees F; Lee D; Patel A; Chhabra N; Baluni G; Amonkar M; Lai Y; Xu R; Massaad R; Fogelman D
    J Med Econ; 2022; 25(1):469-480. PubMed ID: 35184650
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Complementary Roles for Tissue- and Blood-Based Comprehensive Genomic Profiling for Detection of Actionable Driver Alterations in Advanced NSCLC.
    Schwartzberg LS; Li G; Tolba K; Bourla AB; Schulze K; Gadgil R; Fine A; Lofgren KT; Graf RP; Oxnard GR; Daniel D
    JTO Clin Res Rep; 2022 Sep; 3(9):100386. PubMed ID: 36089920
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Health and Budget Impact of Liquid-Biopsy-Based Comprehensive Genomic Profile (CGP) Testing in Tissue-Limited Advanced Non-Small Cell Lung Cancer (aNSCLC) Patients.
    Patel YP; Husereau D; Leighl NB; Melosky B; Nam J
    Curr Oncol; 2021 Dec; 28(6):5278-5294. PubMed ID: 34940080
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.